{"entity":{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","aka":[],"tldr":"Affini-T engineers a patient's T cells with receptors that recognise mutated cancer driver proteins such as KRAS, and uses gene editing to make the cells more effective. It is an early clinical-stage company based near Boston.","summary":"Affini-T Therapeutics is a Watertown, Massachusetts cell therapy company developing T-cell receptor (TCR) based T-cell therapies. Partner Metagenomi reported in August 2024 that it had established cGMP gene-editing reagents and filed Drug Master Files with the FDA to support an IND for Affini-T's TCR-based therapy, receiving 933,650 Affini-T shares on achievement of that regulatory milestone, which indicates the lead programme was at the IND stage in 2024. An SEC Form D filed in October 2024 shows the company was incorporated in 2020 and sold about $17.6 million of equity in an offering that began in July 2024. The company website is rendered client-side and returned no readable text to automated fetches, so programme names, targets and earlier financing rounds could not be confirmed from primary sources.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.affinittx.com/"},{"label":"Form D, October 2024","url":"https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml"},{"label":"Metagenomi Q2 2024 results describing the Affini-T milestone (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-ex99_1.htm"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06105021"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series letter for the 2024 Form D not stated."],"hq":"Watertown, MA","country":"US","companyType":"cell-therapy","website":"https://www.affinittx.com/","founded":2020,"stage":"startup","investors":["leaps-by-bayer"],"funding":[{"round":"Form D offering","year":2024,"amountUsd":17617952,"source":"https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml","note":"Equity offering, first sale 31 July 2024"}]},"route":"/companies/affini-t-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"trial":[{"id":"nct06105021","kind":"trial","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","route":"/trials/nct06105021/"}],"company":[{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/"}]}}